248 related articles for article (PubMed ID: 17555742)
1. Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain.
Guindon J; Desroches J; Dani M; Beaulieu P
Eur J Pharmacol; 2007 Jul; 568(1-3):173-6. PubMed ID: 17555742
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative.
Silva NR; Gomes FV; Fonseca MD; Mechoulam R; Breuer A; Cunha TM; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):369-377. PubMed ID: 28720466
[TBL] [Abstract][Full Text] [Related]
3. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
Fox A; Kesingland A; Gentry C; McNair K; Patel S; Urban L; James I
Pain; 2001 May; 92(1-2):91-100. PubMed ID: 11323130
[TBL] [Abstract][Full Text] [Related]
4. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
5. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain.
Bridges D; Ahmad K; Rice AS
Br J Pharmacol; 2001 Jun; 133(4):586-94. PubMed ID: 11399676
[TBL] [Abstract][Full Text] [Related]
6. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
Liu C; Walker JM
J Neurophysiol; 2006 Dec; 96(6):2984-94. PubMed ID: 16943316
[TBL] [Abstract][Full Text] [Related]
7. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.
Liang YC; Huang CC; Hsu KS
Neuropharmacology; 2007 Jul; 53(1):169-77. PubMed ID: 17572451
[TBL] [Abstract][Full Text] [Related]
8. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Johanek LM; Simone DA
Pain; 2004 Jun; 109(3):432-442. PubMed ID: 15157704
[TBL] [Abstract][Full Text] [Related]
9. Antihyperalgesic effect of the cannabinoid agonist WIN55,212-2 is mediated through an interaction with spinal metabotropic glutamate-5 receptors in rats.
Hama AT; Urban MO
Neurosci Lett; 2004 Mar; 358(1):21-4. PubMed ID: 15016425
[TBL] [Abstract][Full Text] [Related]
10. The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors.
Dani M; Guindon J; Lambert C; Beaulieu P
Eur J Pharmacol; 2007 Nov; 573(1-3):214-5. PubMed ID: 17651722
[TBL] [Abstract][Full Text] [Related]
11. CB2 cannabinoid receptor-mediated peripheral antinociception.
Malan PT; Ibrahim MM; Deng H; Liu Q; Mata HP; Vanderah T; Porreca F; Makriyannis A
Pain; 2001 Sep; 93(3):239-245. PubMed ID: 11514083
[TBL] [Abstract][Full Text] [Related]
12. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.
Nackley AG; Suplita RL; Hohmann AG
Neuroscience; 2003; 117(3):659-70. PubMed ID: 12617970
[TBL] [Abstract][Full Text] [Related]
13. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain.
Costa B; Colleoni M; Conti S; Trovato AE; Bianchi M; Sotgiu ML; Giagnoni G
Br J Pharmacol; 2004 Jan; 141(1):4-8. PubMed ID: 14662732
[TBL] [Abstract][Full Text] [Related]
14. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury.
Brownjohn PW; Ashton JC
Neuroscience; 2012 Feb; 203():180-93. PubMed ID: 22210507
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
Nasirinezhad F; Jergova S; Pearson JP; Sagen J
Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
[TBL] [Abstract][Full Text] [Related]
16. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
17. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Kehl LJ; Hamamoto DT; Wacnik PW; Croft DL; Norsted BD; Wilcox GL; Simone DA
Pain; 2003 May; 103(1-2):175-86. PubMed ID: 12749972
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors.
Abalo R; Cabezos PA; Vera G; López-Miranda V; Herradón E; Martín-Fontelles MI
Neurogastroenterol Motil; 2011 May; 23(5):457-67, e177. PubMed ID: 21303434
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
20. Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.
Fang Q; Han ZL; Li N; Wang ZL; He N; Wang R
Neuropharmacology; 2012 Feb; 62(2):855-64. PubMed ID: 21945715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
